NASDAQ:RGEN

Repligen Stock Forecast, Price & News

$199.64
+9.50 (+5.00 %)
(As of 06/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$188.75
$201.43
50-Day Range
$165.87
$220.95
52-Week Range
$109.38
$228.84
Volume500,484 shs
Average Volume401,867 shs
Market Capitalization$10.96 billion
P/E Ratio137.68
Dividend YieldN/A
Beta0.84
30 days | 90 days | 365 days | Advanced Chart
Receive RGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.


Repligen logo

About Repligen

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.62 out of 5 stars

Medical Sector

413th out of 2,100 stocks

Biological Products, Except Diagnostic Industry

56th out of 198 stocks

Analyst Opinion: 2.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Repligen (NASDAQ:RGEN) Frequently Asked Questions

Is Repligen a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Repligen stock.
View analyst ratings for Repligen
or view top-rated stocks.

What stocks does MarketBeat like better than Repligen?

Wall Street analysts have given Repligen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Repligen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Repligen's next earnings date?

Repligen is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Repligen
.

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) issued its quarterly earnings results on Tuesday, May, 4th. The biotechnology company reported $0.68 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.42 by $0.26. The biotechnology company had revenue of $142.80 million for the quarter, compared to analyst estimates of $117.88 million. Repligen had a net margin of 18.37% and a trailing twelve-month return on equity of 8.39%. The firm's revenue was up 87.6% on a year-over-year basis. During the same period last year, the firm earned $0.32 earnings per share.
View Repligen's earnings history
.

How has Repligen's stock price been impacted by COVID-19 (Coronavirus)?

Repligen's stock was trading at $91.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RGEN stock has increased by 119.4% and is now trading at $199.64.
View which stocks have been most impacted by COVID-19
.

What guidance has Repligen issued on next quarter's earnings?

Repligen issued an update on its FY 2021 earnings guidance on Tuesday, May, 18th. The company provided earnings per share guidance of 2.210-2.280 for the period, compared to the Thomson Reuters consensus estimate of $1.910. The company issued revenue guidance of $565 million-$590 million, compared to the consensus revenue estimate of $513.38 million.

What price target have analysts set for RGEN?

4 equities research analysts have issued 12 month price objectives for Repligen's shares. Their forecasts range from $240.00 to $251.00. On average, they anticipate Repligen's stock price to reach $247.00 in the next year. This suggests a possible upside of 23.7% from the stock's current price.
View analysts' price targets for Repligen
or view top-rated stocks among Wall Street analysts.

Who are Repligen's key executives?

Repligen's management team includes the following people:
  • Tony J. Hunt, President, Chief Executive Officer & Director (LinkedIn Profile)
  • James R. Bylund, Senior Vice President-Global Operations & IT (LinkedIn Profile)
  • Jon K. Snodgres, Chief Financial Officer (LinkedIn Profile)
  • Ralf Kuriyel, Senior Vice President-Research & Development
  • Squire J. Servance, Secretary, Chief Compliance Officer & Senior VP

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen CEO Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among Repligen's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Repligen's key competitors?

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Square (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), The Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Who are Repligen's major shareholders?

Repligen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Fred Alger Management LLC (2.69%), Price T Rowe Associates Inc. MD (2.40%), Select Equity Group L.P. (2.28%), Alliancebernstein L.P. (2.04%), 12 West Capital Management LP (1.99%) and Bank of New York Mellon Corp (1.96%). Company insiders that own Repligen stock include Anthony Hunt, Christine Gebski, James Bylund, John Cox, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends for Repligen
.

Which institutional investors are selling Repligen stock?

RGEN stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Ameriprise Financial Inc., Renaissance Technologies LLC, Friess Associates LLC, Arrowstreet Capital Limited Partnership, Holocene Advisors LP, Federated Hermes Inc., and Dimensional Fund Advisors LP. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, and Thomas F Ryan Jr.
View insider buying and selling activity for Repligen
or view top insider-selling stocks.

Which institutional investors are buying Repligen stock?

RGEN stock was acquired by a variety of institutional investors in the last quarter, including Brown Capital Management LLC, Fred Alger Management LLC, Millennium Management LLC, Price T Rowe Associates Inc. MD, BNP PARIBAS ASSET MANAGEMENT Holding S.A., Public Employees Retirement Association of Colorado, New York State Common Retirement Fund, and Principal Financial Group Inc..
View insider buying and selling activity for Repligen
or or view top insider-buying stocks.

How do I buy shares of Repligen?

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $199.64.

How much money does Repligen make?

Repligen has a market capitalization of $10.96 billion and generates $366.26 million in revenue each year. The biotechnology company earns $59.93 million in net income (profit) each year or $1.65 on an earnings per share basis.

How many employees does Repligen have?

Repligen employs 1,128 workers across the globe.

Does Repligen have any subsidiaries?

The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.

When was Repligen founded?

Repligen was founded in 1981.

What is Repligen's official website?

The official website for Repligen is www.repligen.com.

Where are Repligen's headquarters?

Repligen is headquartered at 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453.

How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at (781) 250-0111 or via email at [email protected]


This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.